Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
April 17, 2014, 06:49:39 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 620058
  • Total Topics: 46716
  • Online Today: 282
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: RV262:Human Clinical Trial of a New DNA-MVA Vaccine Candidate Begins in Africa  (Read 1233 times)

0 Members and 1 Guest are viewing this topic.

Offline ichigo_kun

  • Member
  • Posts: 49
A Phase I clinical trial beginning this month in Kericho, Kenya and later in Tanzania and Uganda, will evaluate a new vaccine combination. Together, these two vaccines aim to protect against diverse subtypes of HIV-1 prevalent in Africa, as well as North America, Europe, Asia and South America.

This small-scale trial, called RV262, will enroll 80 volunteers in East Africa, and will take about 18 months to complete. This study is designed to confirm the vaccine regimen’s safety, and to determine the types of immune responses it stimulates. Eleven HIV-uninfected volunteers in the U.S. have already received the full vaccine regimen to ensure its safety before the trial expanded into East Africa.

This unique prime-boost preventive HIV vaccination strategy is designed for global protection from various strains of HIV. The prime is a plasmid DNA vaccine, PENNVAX™-G, and the boost is a virus vector vaccine, Modified Vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR). Together, the vaccines are designed to deliver a diverse mixture of antigens for HIV subtypes A, B, C, D and E. The MVA component was developed using HIV isolates collected from these East Africa research sites.

Taken separately, DNA based and MVA based vaccine strategies have been shown to be safe and immunogenic in pre-clinical and clinical trials. Researchers hope they can enhance immune responses by using this prime-boost strategy. “The individual vaccine platforms contain inserts specifically designed for HIV protection, targeting different viral subtypes reflecting local circulating strains, and is referred to as a ‘heterologous prime-boost strategy’. The goal is to provide key genetic information to the immune system within different immunologic contexts so as to optimize the response,” noted Dr. Mary Marovich, the study's Principal Investigator.

Another unique factor in this trial is the way one of the vaccines is delivered. DNA vaccines have many advantages, but researchers are still trying to determine the best way to inject it into the body so that it can have maximum potency. To address this, researchers will test two intramuscular delivery methods for the DNA prime (PENNVAX™-G) to compare their effects on immune response. The two devices that will be tested in this study are the Biojector® 2000 and the CELLECTRA® EP (electroporation) device.

The Biojector is a needle-free injection system that has been widely used for delivering vaccines and other injected medications. The CELLECTRA EP system is a new intramuscular electroporation device currently being evaluated in clinical trials as an alternative vaccine delivery system to increase immune responses above those elicited by standard needle and syringe injections. Electroporation involves the application of controlled, millisecond electrical pulses to cells to enhance their uptake of the vaccine.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), is sponsoring the study, which is led by the U.S. Military HIV Research Program (MHRP).  This clinical trial is a collaboration that includes Bioject Medical Technologies Inc., Inovio Pharmaceuticals, Inc., Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., NIAID and the U.S. Army/MHRP.
http://www.hivresearch.org/news.php?NewsID=239

Offline WRD_123

  • Member
  • Posts: 15
I hope it goes over well! It's amazing at all of the ideas people have for vaccines and treatment.

I do wish things could somehow speed up a bit though! ha

Although, I understand that doing things right takes time.. and better to do them right than wrong.

Ps. Did anything ever come of the vaccine that was developed in Thailand and protected 31% of people? I'm including the link to that article:

http://healthland.time.com/2012/04/05/study-explains-how-the-first-effective-hiv-vaccine-worked/


 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.